Envisagenics
Biotechnology Research • 
Queens, New York, United States • 21-50 Employees
Company overview
| Headquarters | 30-02 48th Ave, Ste. 140, New York, NY 11101, US |
| Phone number | +19297772001 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | RNA, Drug Discovery, Artificial Intelligence, AI, Machine Learning, Deep Learning, Splicing |
| Founded | 2014 |
| Employees | 21-50 |
| Socials |
Key Contacts at Envisagenics
Roman Braun
Director Of Business Development
Frankie Cleary
Senior Director Of Engineering & It
Martin Akerman
Cto, Cofounder
Nikolas Giagtzoglou
Senior Director Of Cns Program Research
Miguel A. Manzanares
Director Of Oncology Programs
Alyssa Fronk
Director Of Computational Biology
Tiffany Tsui
Senior Director, Program And Alliance Management
Kendall Anderson
Director Of Target Discovery
Envisagenics Email Formats
Envisagenics uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@envisagenics.com), used 52.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@envisagenics.com | 52.3% |
{first name}{last name} | johndoe@envisagenics.com | 31.8% |
{first initial} | j@envisagenics.com | 6.8% |
{last name}{last name} | doedoe@envisagenics.com | 6.8% |
{first name} | john@envisagenics.com | 2.3% |
About Envisagenics
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
Envisagenics revenue & valuation
| Annual revenue | $2,222,222 |
| Revenue per employee | $48,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $7,200,000 |
| Total funding | $25,000,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Envisagenics has 30 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore Envisagenics's funding history, including investment rounds, total capital raised, and key backers.
Envisagenics Tech Stack
Discover the technologies and tools that power Envisagenics's digital infrastructure, from frameworks to analytics platforms.
Video players
Hosting
WordPress plugins
Maps
JavaScript libraries
CDN
Advertising
Font scripts
JavaScript libraries
Miscellaneous
Programming languages
Portugal
Costa Rica
United Kingdom
Taiwan, Province of China
Jamaica
GermanyFrequently asked questions
4.8
40,000 users
